Developer of therapies designed to provide treatment of retinal diseases. The company's KSI 301 helps to restore vision and stop progression of underlying disease, enabling healthcare providers to cure their patients.
Year Founded
2009
Employees
28
Net IncomeTTM 2Q2018
($324.8 K)
General Information
-
Website
-
Business Status
Pre-Clinical Trials
-
Ownership Status
Publicly Held
-
Financing Status
Formerly VC-backed
Kodiak Sciences News and Updates
Diabetic Retinopathy Market to Expand at a Significant Growth Rate ...
Industry Today | November 30, 2023
Kodiak Sciences (KOD) Price Target Increased by 25.00% to 5.10
Nasdaq | November 27, 2023
Gains in the current understanding of managing neovascular AMD ...
Journal of Ophthalmic Inflammation and Infection | November 23, 2023
Kodiak Sciences to Present at the 6th Annual Evercore ISI ...
PR Newswire | November 21, 2023
Capital One Upgrades Kodiak Sciences (KOD)
Nasdaq | November 18, 2023
MCO-010 optogenetic gene therapy for severe vision loss in ...
Modern Retina | November 17, 2023